Kim Yoon Young, Kim Yong Jin, Cho Kyung Mee, Kim Soo Hyun, Park Kyung Eui, Kang Byeong-Cheol, Jung Kyung Cheon, Kim Moon Suk, Ku Seung-Yup
1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
2Department of Obstetrics and Gynecology, Korea University Guro Hospital, Seoul, Korea.
Tissue Eng Regen Med. 2016 Dec 17;13(6):724-731. doi: 10.1007/s13770-016-0009-y. eCollection 2016 Dec.
Freezing and thawing is one of the most widely used tissue engineering techniques for the preservation of ovaries. Many cells and tissues demonstrate changes in functional gene expression after thawing. Several studies have reported the important roles of angiotensin (AT) system during the ovarian follicular growth. AT system consists of ATII, and ATII receptors type I (ATII-RI) and type II (ATII-RII). However, little is known whether frozen-thawed ovaries show any alteration of AT system member gene expression when treated with survival-enhancing factors. We aimed to investigate whether mass freezing and thawing with or without the use of Rho-associated kinase (ROCK) inhibitors up- or down-regulate the expression of ATII, ATII-RI, and ATII-RII genes on frozen-thawed ovarian tissues. Significant changes in the expression of ATII, ATII-RI, and ATII-RII genes were observed on thawed ovaries when compared to fresh control. The treatment with ROCK inhibitors did not significantly alter their expression. In conclusion, freezing and thawing of ovarian tissue may affect the mRNA expression levels of intra-ovarian AT system genes, and modulation of ROCK inhibitor activity may not regulate AT system on the frozenthawed ovarian tissue.
冷冻和解冻是卵巢保存中应用最广泛的组织工程技术之一。许多细胞和组织在解冻后功能基因表达会发生变化。多项研究报道了血管紧张素(AT)系统在卵泡生长过程中的重要作用。AT系统由ATII以及I型(ATII-RI)和II型(ATII-RII)ATII受体组成。然而,对于经存活增强因子处理的冻融卵巢,AT系统成员基因表达是否会出现改变,人们了解甚少。我们旨在研究在使用或不使用Rho相关激酶(ROCK)抑制剂的情况下,批量冷冻和解冻是否会上调或下调冻融卵巢组织中ATII、ATII-RI和ATII-RII基因的表达。与新鲜对照组相比,在解冻后的卵巢中观察到ATII、ATII-RI和ATII-RII基因表达有显著变化。ROCK抑制剂处理并未显著改变它们的表达。总之,卵巢组织的冷冻和解冻可能会影响卵巢内AT系统基因的mRNA表达水平,而ROCK抑制剂活性的调节可能无法调控冻融卵巢组织上的AT系统。